Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019
November 14 2019 - 6:30AM
Heidelberg, Germany, November 14, 2019 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that it will host a conference call on
Tuesday, November 19, 2019 at 8:30 a.m. ET to discuss its third
quarter 2019 financial results and recent corporate
developments.
The conference call will be available via phone
and webcast. To access the call, please dial +1 (631) 510-7495 for
U.S. callers, or +44 (0) 2071 928000 for international callers, and
reference conference ID 8758067 approximately 15 minutes
prior to the call.
A live audio webcast of the conference call will
be available in the “Webcasts” section on the “Investors” page of
the Affimed website at
https://www.affimed.com/investors/webcasts_cp/, and will be
accessible at the same link for 30 days.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. For
more information, please visit www.affimed.com.
Affimed Investor and Media
Contact:
Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024